Author: Ravi Shankar

Company to host conference call on November 5, 2026, at 4:30 p.m. ET

MOUNTAIN VIEW, Calif., Oct. 22, 2026 (GLOBE NEWSWIRE) — RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath^®, a patented, FDA-cleared drug-delivery device, today announced that it will release third quarter 2026 financial results and business highlights after market close on Thursday, November 5, 2026. RenovoRx will host a conference call and webcast at 4:30 p.m. ET following the release.

During the call, management will discuss the Company’s commercial execution, the drivers of its commercial success, and the foundation it believes is in place for continued revenue growth and cash generation.

Management will also provide an update on clinical progress expected to support greater physician adoption of RenovoRx’s patented Trans-Arterial Micro-Perfusion (TAMP™) platform, enabled by RenovoCath, and expand its use in additional solid tumors indications.

Conference Call Details
Live Call Dial-in:	1-844-826-3033 (U.S. and Canada toll free) 1-412-317-5185 (International)
Webcast:	Access here
Replay:	1-844-512-2921 (U.S. and Canada toll free) 1-412-317-6671 (International) Access ID: 10212350

About RenovoRx, Inc.
RenovoRx, Inc. (Nasdaq: RNXT) is a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath^®, a patented, U.S. Food and Drug Administration (FDA)-cleared local drug-delivery device, targeting high unmet medical needs. RenovoRx’s patented Trans-Arterial Micro-Perfusion (TAMP™) platform is designed for targeted therapeutic delivery across the arterial wall near the tumor site to bathe the target tumor, while potentially minimizing a therapy’s toxicities versus systemic intravenous therapy. RenovoRx’s novel approach to targeted treatment offers the potential for increased safety, tolerance, and improved efficacy, and its mission is to transform the lives of cancer patients by providing innovative solutions to enable targeted delivery of diagnostic and therapeutic agents. RenovoRx is actively commercializing its TAMP technology and FDA-cleared RenovoCath as a standalone device. For its first full year of commercial efforts in 2025, RenovoRx generated approximately $1.1 million in RenovoCath sales, followed by record quarterly revenue of $909,000 in the second quarter of 2026. RenovoRx is actively working to expand the number of medical institutions initiating new RenovoCath orders, including esteemed, high-volume National Cancer Institute-designated centers.

RenovoRx is also evaluating its novel drug-device combination oncology product candidate intra-arterial gemcitabine delivered via RenovoCath (known as IAG) in the ongoing Phase III TIGeR-PaC trial. IAG is being evaluated by the Center for Drug Evaluation and Research (the drug division of the FDA) under a U.S. investigational new drug application that is regulated by the FDA’s 21 CFR 312 pathway. IAG utilizes RenovoCath, which is FDA-cleared for temporary vessel occlusion in applications including arteriography, preoperative occlusion, and chemotherapeutic drug infusion. RenovoRx achieved full enrollment in the TIGeR-PaC trial in August 2026, with completion of the trial expected in the first half of 2027 and topline data readout expected in the second half of 2027.

The IAG combination product candidate, enabled by the RenovoCath device, is currently under investigation and has not been approved for commercial sale. RenovoCath with gemcitabine received Orphan Drug Designation (ODD) for pancreatic cancer and bile duct cancer, and oxaliplatin has received ODD for pancreatic cancer, each of which provides seven years of market exclusivity upon new drug application approval by the FDA.

For more information, visit www.renovorx.com. Follow RenovoRx on Facebook, LinkedIn, and X.

Cautionary Note Regarding Forward-Looking Statements

This press release, the conference call described herein, and statements of the Company’s management and third parties made in connection therewith contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934, including but not limited to statements regarding (i) our clinical trials and studies, (ii) the potential for our product candidates to treat or provide clinically meaningful outcomes for certain medical conditions or diseases, and (iii) our efforts to commercialize our RenovoCath and TAMP technology. Statements that are not purely historical are forward-looking statements. These and other forward-looking statements contained herein are based upon our current expectations and beliefs regarding future events, many of which, by their nature, are inherently uncertain, outside of our control, and involve assumptions that may never materialize or may prove to be incorrect. These may include estimates, projections, and statements relating to our research and development plans, intellectual property development, clinical trials, our therapy platform, business plans, financing plans, objectives, and expected operating results, which are based on such current expectations and assumptions that are subject to significant known and unknown risks and uncertainties that may cause actual results to differ materially and adversely from those expressed or implied by these forward-looking statements. These statements may be identified using words such as “may,” “expects,” “plans,” “aims,” “anticipates,” “believes,” “forecasts,” “aim,” “goal,” “estimates,” “intends,” and “potential,” or derivatives of these terms or other comparable terminology regarding RenovoRx’s statements about the future, although not all forward-looking statements contain these words. Risks, uncertainties and assumptions that could cause actual events to differ materially from those projected or indicated by forward-looking statements, include, without limitation: (i) the risk that our exploration of commercial opportunities for our TAMP technology may not lead to viable, revenue generating operations; (ii) circumstances which would adversely impact our ability to efficiently utilize our cash resources on hand or raise additional funding; (iii) the timing of the initiation, progress, and potential results (including the results of interim analyses) of our preclinical studies, clinical trials, and our research programs; (iv) the possibility that interim results may not be predictive of the outcome of our clinical trials, which may not demonstrate sufficient safety and efficacy to support regulatory approval of our product candidate; (v) that applicable regulatory authorities may disagree with our interpretation of the data, research, and clinical development plans and timelines, and the regulatory process for our product candidates; (vi) future potential regulatory milestones for our product candidates, including those related to current and planned clinical studies; (vii) our ability to use and expand our therapy platform to build a pipeline of product candidates; (viii) our ability to advance product candidates into, and successfully complete, clinical trials; (ix) the timing or likelihood of regulatory filings and approvals; (x) our estimates of the number of patients who suffer from the diseases we are targeting and the number of patients that may enroll in our clinical trials; (xi) the commercialization potential of our product candidates, if approved; (xii) our ability and the potential to successfully manufacture and supply our product candidates for clinical trials and for commercial use, if approved; (xiii) future strategic arrangements and/or collaborations and the potential benefits of such arrangements; (xiv) our estimates regarding expenses, future revenue, capital requirements, needs for additional financing, our ability to obtain additional capital and our ability to maintain the listing of our common stock on Nasdaq; (xv) the sufficiency of our existing cash and cash equivalents to fund our future operating expenses and capital expenditure requirements; (xvi) our ability to retain the continued service of our key personnel and to identify, and hire and retain additional qualified personnel; (xvii) the scope of protection we are able to establish and maintain for intellectual property rights, including our therapy platform, product candidates, and research programs; (xviii) our ability to contract with third-party suppliers and manufacturers and their ability to perform adequately; (xix) the pricing, coverage, and reimbursement of our product candidates, if approved; and (xx) developments relating to our competitors and our industry, including competing product candidates and therapies. Information regarding the foregoing and additional risks may be found in the section entitled “Risk Factors” in documents that we file from time to time with the Securities and Exchange Commission, which can be accessed at https://ir.renovorx.com/sec-filings.

As a result of the foregoing, readers are cautioned to not place undue reliance on forward-looking statements, which do not represent promises or guarantees by RenovoRx. Forward-looking statements included herein are made as of the date hereof, and RenovoRx does not undertake any obligation to update publicly such forward-looking statements to reflect subsequent events or circumstances, except as required by law.

Investor Contact:
ICR Healthcare
Stephanie Carrington or Adanna G. Alexander, PhD
T: 646-277-1282
RenovoRx@ICRHealthcare.com

Media Contact:
STiR Communications
Hannah Williams
T: 803-521-1214
hannah@stir-communications.com

COLUMBUS, Ohio, Oct. 22, 2026 (GLOBE NEWSWIRE) — Worthington Enterprises Inc. (NYSE: WOR), a designer and manufacturer of market-leading brands that improve everyday life by elevating spaces and experiences, today announced it will participate in next month’s Baird Global Industrial Conference in Chicago. President and Chief Executive Officer Joe Hayek and Vice President and Chief Financial Officer Colin Souza will share the company’s strategies for accelerating long-term growth and shareholder value by leveraging the proven Worthington Business System and its three pillars—innovation, transformation and M&A.

The presentation is scheduled for Thursday, November 12 at 1:35 p.m. ET. Individuals unable to attend the in-person event may register to watch virtually at this link. A replay of the session will be posted in the Investor Relations section of the Worthington Enterprises website.

2026 Investor and Analyst Day
Prior to the Baird Conference, Worthington Enterprises is hosting an Investor and Analyst Day in New York City on November 10 at 9:30 a.m. ET. Hayek and Souza, as well as Jimmy Bowes, president, Building Performance Solutions and Steve Caravati, president, Trade & Specialty Solutions, will provide an update on the company’s strategy, financial performance and long-term growth opportunities.

Online participants should register at this link: https://worthington-enterprises-investor-day-2026-11-10.open-exchange.net. Investors and analysts interested in attending the in-person event should contact Marcus Rogier at marcus.rogier@wthg.com.

About Worthington Enterprises
Worthington Enterprises Inc. (NYSE: WOR) is a designer and manufacturer of market-leading brands that improve everyday life by elevating spaces and experiences. Building Performance Solutions (formerly Building Products) delivers essential engineered products that enhance performance across residential and commercial buildings, including critical facilities such as data centers. Its products support building systems, and climate and comfort applications. The segment primarily serves OEMs and distributors. Trade & Specialty Solutions (formerly Consumer Products) includes market-leading brands used by professional tradespeople and consumers across tools, portable propane and helium and other specialty applications. The Worthington Enterprises portfolio includes Balloon Time®, Bernzomatic®, ClarkDietrich, Coleman® propane cylinders, Elgen, General®, HALO™, LEVEL5 Tools®, Ragasco®, Roof Hugger®, Well-X-Trol® and Worthington Armstrong Venture (WAVE), among others.

Headquartered in Columbus, Ohio, Worthington Enterprises employs approximately 4,000 people throughout North America and Europe.

Founded in 1955 as Worthington Industries, Worthington Enterprises follows a people-first Philosophy with earning money for its shareholders as its first corporate goal. Worthington Enterprises achieves this outcome by empowering its employees to innovate, thrive and grow with leading brands in attractive markets that improve everyday life. The company engages deeply with local communities where it has operations through volunteer efforts and The Worthington Companies Foundation, participates actively in workforce development programs and reports annually on its corporate citizenship and sustainability efforts. For more information, visit worthingtonenterprises.com.

Forward-Looking Statements
Statements by Worthington Enterprises that are not limited to historical information constitute “forward-looking statements” under federal securities laws. Forward-looking statements are subject to various risks, uncertainties and other factors that may cause actual results to differ materially from those expected by Worthington Enterprises. Readers should evaluate forward-looking statements in the context of such risks, uncertainties and other factors, many of which are described in Worthington Enterprises’ filings with the Securities and Exchange Commission (“SEC”). Forward-looking statements are qualified by the cautionary statements included in Worthington Enterprises’ SEC filings and other public communications. This press release speaks only as of the date hereof. Worthington Enterprises does not undertake any obligation to update or revise its forward-looking statements except as required by applicable law or regulation.

Sonya L. Higginbotham
Senior Vice President
Chief of Corporate Affairs, Communications and Sustainability
614.438.7391
sonya.higginbotham@wthg.com

Marcus A. Rogier
Treasurer and Investor Relations Officer
614.840.4663
marcus.rogier@wthg.com

200 Old Wilson Bridge Rd.
Columbus, Ohio 43085
WorthingtonEnterprises.com

VANCOUVER, British Columbia, Oct. 22, 2026 (GLOBE NEWSWIRE) — Encore Technologies Corp. (“Encore” or the “Company”) (CSE: ENCR) is pleased to highlight a major on-orbit technology milestone achieved by portfolio company, Solstar Space Co. (“Solstar”), following the successful demonstration of Solstar’s space communications technology during an ongoing NASA proximity operations mission.

Highlights:

• NASA Mission Success: Solstar successfully demonstrated its technology in space during an operational NASA mission.
• Technology Validated in Orbit: Solstar connected two spacecraft and helped deliver NASA mission data back to Earth on the Iridium Network.
• Encore Expands Space Focus: Following its US$1.16 million investment in Solstar, Encore is strengthening its focus and leadership in the rapidly growing space sector.

The milestone comes shortly after Encore’s approximately US$1.16 million strategic investment in Solstar and represents an important validation of the investment thesis behind Encore’s growing exposure to the commercial space economy.

Encore is also announcing the appointment of Company co-founder and capital markets executive Matthew Sroka to its Board of Directors as part of a board reconstitution that will see founding shareholder and Director James Reid resign from the board of directors.

With its investment in Solstar and the recent addition of former Commander of the Royal Canadian Air Force Lieutenant-General (Ret’d) Michael Hood as Strategic Advisor, Encore is building deeper expertise and exposure within the rapidly developing commercial and defence space infrastructure markets.

Solstar Technology Successfully Deployed in Operational NASA Mission

Solstar recently demonstrated its Deke™ Space Communicator during NASA’s R5-S10 proximity operations mission involving NASA’s CubeSat and Momentus’ Vigoride-7 orbital service vehicle.

Solstar’s technology established a space-to-space Wi-Fi connection between the spacecraft, capturing mission imagery and sensor data and relaying mission-critical information back to NASA personnel at Johnson Space Center through the Iridium satellite network. During approximately 30 minutes of proximity operations, Deke collected more than 2,300 files, including imagery and optical, infrared and LiDAR sensor data.

The mission represents a significant milestone for Solstar, advancing its communications architecture from technology development to demonstrated on-orbit capability during an operational NASA mission. The demonstration validated key elements of an end-to-end communications architecture designed to support increasingly connected and autonomous space operations, with potential applications across satellites, orbital servicing, commercial space stations and future lunar operations.

For Encore, the successful mission provides important validation of its investment thesis in Solstar, demonstrating the technology in a live orbital environment alongside NASA, Momentus and Iridium, while reinforcing Encore’s growing focus on the commercial space economy.

Solstar’s Joint News Release with NASA

Stephen Kukucha, Chief Executive Officer of Encore, commented:

“When we invested in Solstar, we believed communications infrastructure would become increasingly critical as activity in orbit expands. What Solstar has now accomplished with NASA is an important validation of that thesis.

This wasn’t a laboratory demonstration. Solstar’s technology operated in space during a NASA mission, connected spacecraft in orbit and helped move mission data back to Earth through the Iridium network. That is an important distinction.

We believe the next generation of space infrastructure will require persistent and reliable connectivity between spacecraft, operators and Earth. Solstar is building technology aimed directly at that requirement, and we believe this successful mission materially strengthens its position as the commercial space economy develops.”

Board Reconstitution

Encore is also pleased to announce the appointment of Matthew Sroka, a co-founder of Encore and Managing Partner of Three Peaks Capital, to the Company’s Board of Directors.

Mr. Sroka has more than 16 years of experience across international capital markets, corporate finance and company formation. He has played a senior role in more than $200 million of public and private financings and has helped build, finance and structure companies and transactions across multiple international markets and stock exchanges. His experience spans capital formation, corporate structuring, M&A, institutional investor development and the advancement of emerging companies from early-stage formation through public-market growth.

Mr. Sroka’s appointment adds significant capital markets and corporate development experience to the Board as Encore evaluates opportunities to expand its exposure to emerging technology and infrastructure markets.

In connection with the Board reconstitution, James Reid will resign as a director of the Company.

Encore extends its sincere appreciation to Mr. Reid for his contributions as a founding director and for his important role in guiding the Company through its formation and successful listing on the Canadian Securities Exchange.

About Solstar Space Company

Solstar is a U.S.-based communications infrastructure company developing connectivity solutions for the growing space economy. The Company is focused on enabling persistent communications for spacecraft, commercial space operators, government agencies and future space-based infrastructure through a combination of communications hardware, software and communications services. Solstar’s DEKE Space Communicator is currently operating in orbit, supporting the Company’s mission of extending connectivity beyond traditional terrestrial networks.

About Encore Technologies Inc.

Encore Technologies Inc. is a technology-focused public company advancing intelligent infrastructure solutions and evaluating strategic opportunities in emerging technology sectors. The Company seeks to identify technologies and partnerships that have the potential to improve connectivity, operational efficiency and long-term infrastructure resilience.

For further information contact:
Stephen Kukucha
Chief Executive Officer
Tel: (604) 398-4786

Caution Regarding Forward-Looking Information

This news release contains “forward-looking information” within the meaning of applicable Canadian securities laws. Forward-looking information includes statements regarding, the proposed Financing, the proposed Investment, the execution of definitive agreements, the use of proceeds, anticipated strategic benefits, potential future collaboration opportunities between Encore and Solstar, the completion of the transactions described herein, and other statements that are not historical facts. Forward-looking information is generally identified by words such as “expects,” “intends,” “anticipates,” “believes,” “plans,” “estimates,” “may,” “could,” “would,” “should,” and similar expressions. Forward-looking information reflects management’s current beliefs and assumptions and is subject to a number of known and unknown risks, uncertainties, and other factors that may cause actual results, performance, or achievements to differ materially from those expressed or implied.

Readers are cautioned not to place undue reliance on forward-looking information. The Company undertakes no obligation to update or revise forward-looking information except as required by applicable law.

The CSE has neither approved nor disapproved the contents of this news release. The CSE does not accept responsibility for the adequacy or accuracy of this news release.

NASHVILLE, Tenn., Oct. 22, 2026 (GLOBE NEWSWIRE) — Holley Performance Brands (NYSE: HLLY), a leader in automotive aftermarket performance solutions, today announced the date for the release of its third quarter 2026 financial results.

Third Quarter 2026 Results        
Holley will host a conference call and live webcast on Thursday, November 5, 2026, at 8:30 am (Eastern Time) to discuss the Company’s third quarter 2026 financial results. The Company’s earnings release and presentation for the third quarter 2026 will be issued before the market opens on Thursday, November 5, 2026, and will be available on the Investor Relations page of the Company’s website at investor.holley.com.

Hosting the call will be Holley Inc. President and Chief Executive Officer, Matthew Stevenson, and Chief Financial Officer, Jesse Weaver.                        

Date:	Thursday, November 5, 2026
Time:	8:30 a.m. Eastern Time
Dial-In #:	United States: 1-877-407-4019 (Toll Free)
	United States: 1-201-689-8337 (Toll)

Access Code: 13763297
        
Alternatively, the conference call will be webcast at:

Event URL: https://event.choruscall.com/mediaframe/webcast.html?webcastid=n5skJ2NR

For those unable to participate, a telephone replay recording will be available until Thursday, November 12, 2026. To access the replay, please call 877-660-6853 (Toll Free) or 201-612-7415 (Toll) and enter confirmation code 13763297. A web-based archive of the conference call will also be available at the Company’s website.

About Holley Performance Brands
Holley Performance Brands (NYSE: HLLY) is home to a portfolio of iconic brands that serve enthusiasts across the high-performance aftermarket. The company designs, engineers, manufactures and markets category-leading products and solutions for automotive enthusiasts through a focused portfolio spanning four consumer vertical groupings: American Performance, Modern Truck & Off-Road, Euro & Import, and Safety & Racing. For more than a century, Holley has built its reputation through innovation, technical expertise and a deep understanding of enthusiast culture. For more information, visit https://www.holley.com.

Contact:        
Investor Relations: 
Sloan Bohlen / Jenna Kozlowski
Solebury Strategic Communications
203-428-3225
holley@soleburystrat.com

Media Relations Contacts: 
Nathan Espinosa / Patrick Curtin
Kahn Media
818-881-5246
holley@kahnmedia.com 

AAA Four Diamond property becomes MBody’s first multi-year commercial partner in Florida, extending the company’s physical AI business beyond casino-resorts

Highlights

• First non-casino resort customer and first commercial account in Florida.
• MBody will provide Caribe Royale Orlando physical AI hardware, service & its proprietary Orchestrator™ software.

LAS VEGAS and ORLANDO, Fla., Oct. 22, 2026 (GLOBE NEWSWIRE) — MBody AI Ltd. (“MBody AI” or the “Company”) (Nasdaq: MBAI) today announced Caribe Royale Orlando as a new commercial partner. The AAA Four Diamond property is MBody’s first commercial resort partnership in Florida.

Proprietary MBody AI Orchestrator™ platform coordinates autonomous equipment from different manufacturers. The Company combines the software with deployment and ongoing service through its AI-as-a-Service model, which is built around multiyear subscriptions.

Caribe Royale Orlando brings the scale of a major convention destination together with the personal attention of an independently owned resort. Its AAA Four Diamond property features 1,217 one-bedroom suites, 120 two-bedroom villas and 260,000 square feet of indoor and outdoor event space. Eight dining venues, including The Venetian Chop House and Stadium Club, serve guests whose visits range from family vacations to large conferences.

Delivering a consistent experience across those settings takes a coordinated effort behind the scenes. The new relationship brings MBody AI’s offering to a resort where the quality of daily operations is part of the guest experience.

“Every part of Caribe Royale Orlando should reflect the care our team puts into a guest’s stay,” said Luciano Sperduto, Hotel Manager of Caribe Royale Orlando. “We’re thoughtful about the technology we bring into the resort. Working with MBody gives us the physical AI to support our team as we continue investing in the experience we deliver.”

“Caribe Royale Orlando combines the character of an independently owned resort with the scale of a major convention destination,” said John Fowler, Chief Executive Officer of MBody AI. “Luciano and his team understand that an exceptional guest experience depends on what happens behind the scenes. Our focus is helping them put physical AI to practical use in daily operations, supporting their people so they can devote more attention to the service that makes guests return while simultaneously lower their own operating costs.”

MBody’s proprietary AI Orchestrator platform coordinates autonomous equipment from multiple manufacturers, backed by deployment and ongoing service. Caribe Royale Orlando becomes MBody’s first resort partner that is not affiliated with a casino and first commercial deployment in Florida, extending its business beyond gaming. MBody’s strategy is to build lasting customer relationships by making Orchestrator useful across more of their operations. As customers add applications, they can address additional operating needs through a platform they already use, while MBody grows recurring software and service fees alongside the work it supports.

Follow the Company’s progress at ir.mbody.ai

About MBody AI Ltd.

MBody AI Ltd. (Nasdaq: MBAI) is building the enterprise operating layer for physical AI. Its proprietary MBody AI Orchestrator platform manages supported robots from multiple manufacturers, with a commercial focus on hospitality and gaming. MBody combines software, deployment and service under long-term agreements to help customers put robotic workforces to work. Learn more at ir.mbody.ai.

Forward-looking statements

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements in quotations, headlines, highlights and graphics. These statements concern expected benefits of the Caribe Royale Orlando relationship and support for resort operations; growth in standalone resorts and Florida; continuation and expansion of customer relationships; future capabilities and adoption of MBody AI Orchestrator; and growth through additional applications, hardware integrations, properties and customers. Words such as “expect,” “believe,” “intend,” “may,” “will” and similar expressions identify some, but not all, forward-looking statements.

These statements reflect management’s current expectations and assumptions regarding customer demand, technology performance, supplier availability and the Company’s financing and service capacity. Actual results may differ materially due to risks including equipment or software failures, integration difficulties, cybersecurity incidents or service interruptions; anticipated benefits not being achieved or sustained; changes in customer requirements or budgets; customer concentration, reduced orders, termination or non-renewal of engagements; delays in developing supported applications or integrations; dependence on third-party manufacturers and suppliers; equipment, personnel and service availability and costs; inability to convert pilots or expand accounts; competition and market conditions; additional capital requirements, financing availability and potential dilution; failure to maintain Nasdaq listing compliance or foreign private issuer status; and other risks described in the Company’s filings with the U.S. Securities and Exchange Commission.

Past results and customer expansion do not guarantee future performance, further orders or deployments at other properties. Forward-looking statements are not guarantees of future operating results. Readers should not place undue reliance on these statements, which speak only as of this release’s date. Except as required by law, the Company undertakes no obligation to update or revise forward-looking statements for new information, future events or otherwise.

Quick Facts

Issuer:	MBody AI Ltd. (NASDAQ: MBAI)
Listing:	Nasdaq Capital Markets
Sector:	Technology
Industry:	Embodied AI and enterprise robotics (physical AI)
Event:	New Customer Announcement. First resort customer in Florida
Caribe Royale Orlando	AAA Four Diamond property, 1,217 one-bedroom suites, 120 two-bedroom villas and 260,000 square feet of indoor and outdoor event space
Location:	8101 World Center Drive, Orlando, Florida 32821
CUSIP	M6S83C106

Investor relations
Lytham Partners, LLC
602-889-9700 | ir@mbody.ai

Media contact
Core IR | ir@mbody.ai

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/73fed1aa-ddd2-4107-bbdd-3550457432be.

Courses generate at runtime in their true surroundings, so the library keeps growing while installs stay light across 19 launch monitors and every TruGolf Links franchise location

E6 by TruGolf generates each course at runtime in its true surroundings using Cesium for Unreal.

SALT LAKE CITY, Oct. 22, 2026 (GLOBE NEWSWIRE) — TruGolf Holdings, Inc. (Nasdaq: TRUG) today announced that E6 by TruGolf now offers more than 15,000 real-world golf courses on demand, up 50% in under a year. Because courses are delivered on demand, the library can keep growing without making the software heavier to install. Because E6 supports 19 launch monitors, every new course reaches golfers who own other brands’ hardware. Because every TruGolf Links franchise location runs E6, the whole franchise network plays on the same platform and library.

The enabling technology is Cesium for Unreal. E6 generates each course at runtime, places it at its true location on the globe, and delivers only the data a player’s round requires. That keeps the application responsive, reduces bandwidth and storage costs, and lets golfers move from one course to the next almost immediately. Cesium, part of Bentley Systems, Incorporated (Nasdaq: BSY), has published a user story and video on TruGolf’s work at cesium.com.

E6 in numbers

• On-demand course play in E6 Golf 2026 grew nearly sixfold year over year.
• Golfers explored more than four times as many on-demand courses as the year before.
• Shots played on on-demand courses grew more than sevenfold year over year.
• Rounds played on E6 Golf 2026 more than tripled year over year.
• On-demand courses now account for more than 40% of course rounds in E6 Golf 2026, up from about 30% a year ago.
• Golfers have hit hundreds of millions of shots on the E6 platform since 2022.

“Software is where this business compounds,” said Brenner Adams, TruGolf’s Chief Executive Officer. “Every course we add makes E6 more valuable to every subscriber and venue already on it, and it adds nothing to the install. Because E6 runs on 19 launch monitors, our market is every golfer with a simulator, not only golfers with our hardware. And every TruGolf Links franchise location opens with the full library from day one. That is a recurring software business that scales with its content.”

Each course is built from a combination of public and high-resolution private datasets, processed to support accurate ball physics. Cesium ion then streams the world around it, including Google Photorealistic 3D Tiles and Bing Maps imagery, and Cesium’s geospatial coordinate systems place every dataset at its true location. TruGolf adds auto-populated vegetation and player controls for time of day, weather, and atmospheric effects. A player can tee off in Las Vegas with the Sphere on the skyline, putt along the coast at Pebble Beach, or play Park City with the Wasatch Mountains rising behind the green.

“Golfers judge a simulator by two things: how many courses they can play and how real those courses feel,” said Jake Johnson, VP Software at TruGolf. “Delivering each course on demand lets us keep adding to a library of more than 15,000 courses without asking players to download large amounts of data to their devices. Cesium surrounds every one of those courses with the real world, rendered with stunning accuracy. That combination is what lets the platform scale.”

E6 reads a player’s swing through launch monitors that use camera or LiDAR sensors to measure spin, speed, and impact, and turns that data into realistic ball flight and detailed analytics that help players improve. E6 is used in restaurants and hospitality venues, dedicated golf centers, TruGolf Links franchise locations, and home game rooms worldwide.

“TruGolf demonstrates the power of real-world data to create highly realistic, immersive simulation environments,” said Jillian Long, Business Development Manager, Cesium. “Golfers stand in the actual landscape of each course, streamed on demand from Cesium ion.”

See E6 in action

Video: youtu.be/dhlmSTiEzkQ

Cesium user story: cesium.com/blog/2026/10/22/trugolf-creates-courses-in-cesium-for-unreal

Investors: investors@trugolf.com

About TruGolf

Since 1983, TruGolf has been passionate about driving the golf industry with innovative indoor golf solutions. TruGolf builds products that capture the spirit of golf. TruGolf’s mission is to help grow the game by attempting to make it more Available, Approachable, and Affordable through technology, because TruGolf believes Golf is for Everyone. TruGolf’s team has built award-winning video games (“Links”), innovative hardware solutions, and an all-new e-sports platform to connect golfers around the world with E6. Since TruGolf’s beginning, TruGolf has continued to attempt to define and redefine what is possible with golf technology.

About Cesium

Cesium is the open platform for creating 3D geospatial applications. Cesium has created open source offerings like CesiumJS, Cesium for Unreal, and Cesium for Unity, as well as 3D Tiles, the Open Geospatial Consortium community standard for streaming massive 3D geospatial datasets. Cesium is part of Bentley Systems, Incorporated (Nasdaq: BSY). Learn more at cesium.com.

Forward-Looking Statements

This news release contains certain statements that constitute “forward-looking statements” within the meaning of the United States Private Securities Litigation Reform Act of 1995. Such statements that are not of historical fact constitute “forward-looking statements” and accordingly, involve estimates, assumptions, forecasts, judgments and uncertainties. The Company has attempted to identify forward-looking statements by terminology including “believes,” “estimates,” “anticipates,” “expects,” “plans,” “projects,” “intends,” “potential,” “may,” “could,” “might,” “will,” “should,” “approximately,” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Forward-looking statements include, without limitation, statements regarding TruGolf’s expectations concerning the continued expansion of the E6 course library, future growth in user engagement, rounds played, shots played, adoption of on-demand course offerings, the scalability and performance of the E6 platform, the benefits of the Company’s technology and content strategy, the growth and operation of TruGolf Links franchise locations, and other statements that are not historical facts. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors. These risks and uncertainties include, among others, changes in market conditions, customer demand and adoption of the Company’s products and services, the Company’s ability to continue expanding and enhancing the E6 platform and course library, the availability and performance of third-party technologies and data sources, the success of the Company’s franchise and software initiatives, competitive pressures, and economic conditions. Any forward-looking statements contained in this release speak only as of its date. The Company undertakes no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events. More detailed information about the risks and uncertainties affecting the Company is contained under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K and subsequently filed Quarterly Reports on Form 10-Q and Current Reports on Form 8-K filed with the SEC, which are available on the SEC’s website, www.sec.gov.

Contacts

Investors: investors@trugolf.com
Media: press@polymath.network

###

Attachment

• TruGolf Holdings, Inc.

LOS ANGELES, Oct. 22, 2026 (GLOBE NEWSWIRE) — Playboy, Inc. (Nasdaq: PLBY) (“Playboy” or the “Company”), a global pleasure and leisure company, will release financial results for the third quarter ended September 30, 2026 after Nasdaq closes on Thursday, November 5, 2026.

Management will host an investor conference call at 5:00 p.m. Eastern time on Thursday, November 5, 2026, to discuss the Company’s third quarter 2026 financial results, provide a corporate update, and conclude with taking questions from telephone participants. To participate, please use the following information:

Q3 2026 Earnings Conference Call
Date: Thursday, November 5, 2026
Time: 5:00 p.m. Eastern time
U.S. Dial-in: 1-877-423-9813
International Dial-in: 1-201-689-8573
Conference ID: 13762643
Webcast: https://viavid.webcasts.com/starthere.jsp?ei=1776030&tp_key=ac4d988b5b

Please join at least five minutes before the start of the call to ensure timely participation.

A telephone playback of the call will be available through Saturday, December 5, 2026. To listen, please call 1-844-512-2921, using replay pin number 13762643. A webcast replay will be available using the webcast link above.

About Playboy, Inc.

Playboy (Nasdaq: PLBY) is a global pleasure and leisure company, built on one of the most globally recognized brands. By leveraging its iconic intellectual property, Playboy pursues an asset-light model across licensing, digital content, consumer products and experiential offerings, helping consumers worldwide to live more fulfilling lives. To learn more, please visit https://investors.playboy.com.

Investor Relations Contact
Lucas A. Zimmerman
Managing Director
MZ Group – MZ North America
+1 (949) 259-4987
PLBY@mzgroup.us
www.mzgroup.us

Major Commercial Milestone Represents Important Step Toward Potential Long-Term Collaborations with Global Pharmaceutical Companies

EDEN PRAIRIE, Minn., Oct. 22, 2026 (GLOBE NEWSWIRE) — NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) (“NeuroOne” or the “Company”), a medical technology company dedicated to transforming the surgical diagnosis and treatment of neurological disorders, today announced that it has secured its first pharmaceutical industry purchase order for the StereoCED™ Drug Delivery Platform to support a preclinical animal research program for a Tier 1 global pharmaceutical company.

The research program is expected to commence in large animals early next year. The study will leverage StereoCED’s unique combination of targeted intracranial drug delivery and electrophysiological recording capabilities, which the Company believes is the only integrated platform of its kind. Unlike other leading drug delivery devices that are not intended for implantation, StereoCED™ is designed to support extended implantation of the electrode for less than 30 days, enabling longitudinal neurological EEG monitoring before and after drug administration. This capability could provide valuable insights into the therapeutic agent’s biological activity and efficacy over time.

This first pharmaceutical industry purchase order represents a significant commercial milestone for NeuroOne and an important step in its strategy to establish StereoCED™ as a preferred drug delivery platform for the global pharmaceutical industry. By engaging with pharmaceutical partners early in therapeutic development, NeuroOne aims to establish its technology as an integral part of the drug development process. As programs advance from preclinical research through human clinical trials and potentially commercialization, continuity with an established delivery platform may reduce development complexity and create opportunities for long-term partnerships and recurring revenue.

“We said we would complete development of StereoCED™ in fiscal Q4, and we delivered,” said David Wambeke, Chief Business Officer of NeuroOne. “With our first purchase order supporting a tier 1 global pharmaceutical company and StereoCED current availability for human investigational clinical studies, we are entering an exciting new phase. We believe StereoCED offers capabilities that competing drug delivery platforms do not, which positions NeuroOne to play an important role in the development of next-generation brain therapies.”

About NeuroOne

NeuroOne Medical Technologies Corporation is a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders. NeuroOne markets a minimally invasive and high-definition/high-precision electrode technology platform with four FDA-cleared product families: Evo^® Cortical Electrodes, Evo^® sEEG Electrodes, OneRF^® Ablation System (for brain), and OneRF^® Trigeminal Nerve Ablation System.

NeuroOne has also developed the StereoCED™ platform for targeted intracranial drug delivery, which is currently available for animal research and approved investigational clinical studies. StereoCED™ has not been cleared or approved by the FDA or any other regulatory agency. These solutions offer the potential to reduce the number of hospitalizations and surgical procedures, lower costs, and improve patient outcomes by offering diagnostic and therapeutic functions. The Company is engaged in research and development for basivertebral nerve ablation and spinal cord stimulation programs. For more information, visit nmtc1.com.

Forward Looking Statements

This press release may include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Except for statements of historical fact, any information contained in this press release may be a forward–looking statement that reflects NeuroOne’s current views about future events and are subject to known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. In some cases, you can identify forward–looking statements by the words or phrases “may,” “might,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “objective,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “target,” “seek,” “contemplate,” “continue, “focused on,” “committed to” and “ongoing,” or the negative of these terms, or other comparable terminology intended to identify statements about the future. Forward–looking statements may include statements regarding the potential for long-term collaborations with global pharmaceutical companies, the establishment of StereoCED™ as a preferred drug delivery platform for the global pharmaceutical industry.. Although NeuroOne believes that we have a reasonable basis for each forward-looking statement, we caution you that these statements are based on a combination of facts and factors currently known by us and our expectations of the future, about which we cannot be certain. Our actual future results may be materially different from what we expect due to factors largely outside our control, including risks that our partnerships may not facilitate the commercialization or market acceptance of our technology; whether due to supply chain disruptions, labor shortages, risks that our technology will not perform as expected based on results of our pre-clinical and clinical trials; risks related to uncertainties associated with the Company’s capital requirements to achieve its business objectives and ability to raise additional funds: the risk that we may not be able to secure or retain coverage or adequate reimbursement for our technology; uncertainties inherent in the development process of our technology; risks related to changes in regulatory requirements or decisions of regulatory authorities; that we may not have accurately estimated the size and growth potential of the markets for our technology; risks related to our ability to protect our intellectual property rights; and other risks, uncertainties and assumptions, including those described under the heading “Risk Factors” in our filings with the Securities and Exchange Commission. These forward–looking statements speak only as of the date of this press release and NeuroOne undertakes no obligation to revise or update any forward–looking statements for any reason, even if new information becomes available in the future.

IR Contact
MZ Group – MZ North America
NMTC@mzgroup.us

Disclaimer: NeuroOne’s StereoCED™ Drug Delivery System is not approved/cleared for commercial use by any Regulatory agency.

ST. GALLEN, Switzerland, Oct. 22, 2026 (GLOBE NEWSWIRE) — Sportradar Group AG (Nasdaq: SRAD) (“Sportradar”) will release its financial and operating results for the third quarter ended September 30, 2026, on Tuesday, November 3, 2026. Sportradar will also host an earnings call via webcast to discuss the results at 8:30 a.m. Eastern Time on Tuesday, November 3, 2026.

Those wishing to either listen to, or participate in, the earnings webcast can do so by accessing Sportradar’s Investor Relations website at https://investors.sportradar.com. Additionally, a replay will be posted on the Investor Relations website for one year after the conclusion of the event.

About Sportradar
Sportradar Group AG (NASDAQ: SRAD), founded in 2001, is a leading global sports technology company creating immersive experiences for sports fans and bettors. Positioned at the intersection of the sports media and betting/gaming industries, Sportradar provides betting and iGaming operators, media and technology companies, prediction market partners and sports federations with a best-in-class range of solutions to help grow their businesses. Trusted by the world’s leading global sports organizations including the ATP, NBA and WNBA, NHL, MLB, MLS, PGA TOUR, UEFA, FIFA, CONMEBOL, AFC, and the Bundesliga, and global clients including Flutter, DraftKings, Google, Microsoft, Kalshi and Polymarket, Sportradar covers more than a million events annually across all major sports. Sportradar is not just redefining the sports fan experience, it also safeguards sports through its Integrity Services division and advocates for an integrity-driven environment for all involved.

For more information about Sportradar, please visit www.sportradar.com

Investor Relations Contact:
Jim Bombassei
j.bombassei@sportradar.com

Press Contact:
Sandra Lee
sandra.lee@sportradar.com

BURLINGTON, Mass., Oct. 22, 2026 (GLOBE NEWSWIRE) — Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company will report its third quarter 2026 financial results on Thursday, November 5, 2026. Vericel’s management will host a conference call and webcast at 8:30 a.m. ET to discuss its financial results and business highlights.

The live webcast can be accessed on the Investor Relations section of the Vericel website at http://investors.vcel.com/events-presentations. Presentation slides for the conference call will be available on the webcast and on the website. A replay of the webcast will be available until November 5, 2027.

To participate by telephone, dial 800-330-6730 or +1-312-471-1351 if connecting from outside the U.S. When connected, please use passcode: 787594.

About Vericel Corporation

Vericel is a leading provider of advanced therapies for the sports medicine and severe burn care markets. The Company combines innovations in biology with medical technologies, resulting in a highly differentiated portfolio of innovative cell therapies and specialty biologics that repair injuries and restore lives. Vericel markets three products in the United States. MACI® (autologous cultured chondrocytes on porcine collagen membrane) is an autologous cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Epicel® (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to 30% of total body surface area. Vericel also holds an exclusive license for North American rights to NexoBrid® (anacaulase-bcdb), a biological orphan product containing proteolytic enzymes, which is indicated for eschar removal in adults and pediatric patients with deep partial-thickness and/or full-thickness burns. For more information, please visit www.vcel.com. Epicel and MACI are registered trademarks of Vericel Corporation. NexoBrid is a registered trademark of MediWound Ltd. and is used under license to Vericel Corporation. © 2026 Vericel Corporation. All rights reserved.

Investor Contact:

Eric Burns
ir@vcel.com
+1 (734) 418-4411